Landos Biopharma Statistics
Total Valuation
LABP has a market cap or net worth of $70.24 million. The enterprise value is $41.18 million.
| Market Cap | 70.24M |
| Enterprise Value | 41.18M |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LABP has 3.13 million shares outstanding. The number of shares has decreased by -4.27% in one year.
| Shares Outstanding | 3.13M |
| Shares Change (YoY) | -4.27% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 9.89% |
| Owned by Institutions (%) | 51.58% |
| Float | 1.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.03 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.43, with zero debt.
| Current Ratio | 4.43 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -23.65 |
Financial Efficiency
Return on equity (ROE) is -73.00% and return on invested capital (ROIC) is -110.32%.
| Return on Equity (ROE) | -73.00% |
| Return on Assets (ROA) | -63.00% |
| Return on Capital (ROIC) | -110.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.31M |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +649.00% in the last 52 weeks. The beta is 0.14, so LABP's price volatility has been lower than the market average.
| Beta (1Y) | 0.14 |
| 52-Week Price Change | +649.00% |
| 50-Day Moving Average | 18.59 |
| 200-Day Moving Average | 7.88 |
| Relative Strength Index (RSI) | 77.65 |
| Average Volume (30 Days) | 25,261 |
Short Selling Information
The latest short interest is 1,425, so 0.05% of the outstanding shares have been sold short.
| Short Interest | 1,425 |
| Short Previous Month | 803 |
| Short % of Shares Out | 0.05% |
| Short % of Float | 0.11% |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.54M |
| Pretax Income | -24.80M |
| Net Income | -24.80M |
| EBITDA | -23.79M |
| EBIT | -23.79M |
| Earnings Per Share (EPS) | -$3.99 |
Balance Sheet
The company has $29.05 million in cash and no debt, giving a net cash position of $29.05 million or $9.29 per share.
| Cash & Cash Equivalents | 29.05M |
| Total Debt | n/a |
| Net Cash | 29.05M |
| Net Cash Per Share | $9.29 |
| Equity / Book Value | 23.15M |
| Book Value Per Share | 7.41 |
| Working Capital | 23.15M |
Cash Flow
| Operating Cash Flow | -20.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | -20.81M |
| FCF Per Share | -$3.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LABP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.27% |
| Shareholder Yield | 4.27% |
| Earnings Yield | -35.31% |
| FCF Yield | -29.62% |
Analyst Forecast
The average price target for LABP is $20.42, which is -9.12% lower than the current price. The consensus rating is "Hold".
| Price Target | $20.42 |
| Price Target Difference | -9.12% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 26, 2023. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 26, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |